Loading organizations...
§ Private Profile · Seoul, Seoul-t'ukpyolsi, South Korea
Biotechnology company developing cell and gene therapies using MSC technology and Affimer proteins for immune-mediated diseases.
AffyXell Therapeutics is a Seoul, South Korea-based biotechnology company that develops novel cell and gene therapies using mesenchymal stem cell technology and a proprietary protein platform to treat severe immune and inflammatory diseases. Operating with fewer than 25 employees and generating under $5 million in estimated annual revenue, the enterprise engineers stem cells to produce therapeutic proteins directly within the patient. The business has successfully raised $7.3 million in Series A funding from a syndicate of venture capital firms, including Samsung Venture Investment and Kolon Investment. Additionally, the firm maintains strategic partnerships with major industry players like LG Chem Life Sciences to advance its preclinical pipeline and commercialize its proprietary treatments. Currently led by Chief Executive Officer Jong-Sang Ryu, AffyXell Therapeutics was established in 2020 as a joint venture founded by Daewoong Pharmaceutical and Avacta Group.
AffyXell Therapeutics has raised $7.3M across 1 funding round.
AffyXell Therapeutics has raised $7.3M in total across 1 funding round.
AffyXell Therapeutics has raised $7.3M across 1 funding round. Most recently, it raised $7.3M Series A in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $7.3M Series A | — | Gyeongnam Venture Investment, Kolon Investment, Samsung, Shinhan Securities, Shinhan Venture Investment, Smilegate Investment, Stonebridge Ventures | Announced |
AffyXell Therapeutics has raised $7.3M in total across 1 funding round.
AffyXell Therapeutics's investors include Gyeongnam Venture Investment, Kolon Investment, Samsung, Shinhan Securities, Shinhan Venture Investment, Smilegate Investment, Stonebridge Ventures.